Table 2.
Adult HL trials
| Reference | Trial acronym | Stage | Risk | Treatment | PFS | OS | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study arm | Survival | % | Study arm | Survival | % | |||||
| 99 | UK RAPID | IA, IIA (early) | ABVD × 3-4 ± IFRT | RT | 3-y | 94.6 | ||||
| No RT | 3-y | 90.8 | ||||||||
| 30 | CALGB-50604 | I and II (no bulk) | Low | ABVD × 4 (if PET2 negative) | 3-y | 92 | ||||
| ABVD × 2 plus BEACOPP × 2 + IFRT (if PET2 positive) | 3-y | 65 | ||||||||
| 27 | GHSG HD6 | IA, IIA (no bulk) | Low | ABVD × 4-6 cycles | ABVD | 12-y† | 87 | ABVD | 12-y | 94 |
| 20 Gy subtotal nodal RT ± 2 cycles of ABVD | RT ± ABVD | 12-y† | 92 | RT ± ABVD | 12-y | 87 | ||||
| 28, 100 | HD2000 | Early (nonbulky) | Unfavorable | ABVD × 4 + 30 Gy IFRT | 10-y | 69 | 85 | |||
| BEACOPP × 2, ABVD × 2, 30 Gy IFRT | 10-y | 75 | 84 | |||||||
| COPP-EBV-CAD | 10-y | 76 | 86 | |||||||
| 101 | GHSG HD15 | IIB (advanced, with bulky disease), III, IV | escBEACOPP × 8 | 5-y* | 84.4 | 91.9 | ||||
| escBEACOPP × 6 | 5-y* | 89.3 | 95.3 | |||||||
| BEACOPP × 8 | 5-y* | 85.4 | 94.5 | |||||||
| 31 | SWOG S0816 | Advanced | Interim PET-directed after ABVD × 2 | |||||||
| ABVD × 4 (PET negative) | 2-y | 64 | ||||||||
| escBEACOPP × 6 (PET positive) | 2-y | 82 | ||||||||
| 102 | RATHL | Advanced | Unfavorable | ABVD × 2 | 3-y | 85.7 | 97.2 | |||
| ABVD × 4 vs AVD × 4 (PET negative) | AVD | 3-y | 84.4 | 97.6 | ||||||
| BEACOPP vs BEACOPP-14 (PET positive) | BEACOPP | 3-y | 67.5 | 87.7 | ||||||
AVD, doxorubicin, vinblastine, and dacarbazine; COPP-EBV-CAD, cyclophosphamide, vincristine, procarbazine, and prednisone-epirubicin, bleomycin, and vinblastine-cyclophosphamide, doxorubicin, and dexamethasone; escBEACOPP, escalated BEACOPP; GHSG, German Hodgkin Study Group; RATHL, Response Adapted Therapy in Advanced Hodgkin Lymphoma; SWOG, Southwest Oncology Group.
*
Freedom from treatment failure.
†
Freedom from disease progression.